Abstract
Graves disease, an autoimmune disorder, is the most common cause of hyperthyroidism. Graves disease is associated with antibodies against the thyrotropin receptor that stimulate the receptor and promote synthesis and secretion of thyroglobulin and follicular cell proliferation. Patients present with goiter and symptoms of hyperthyroidism, including anxiety, tachycardia, palpitations, tremor, heat sensitivity, and weight loss, and may develop ophthalmopathy and dermopathy. Patients may be treated symptomatically with β-blockers and with antithyroid medications (propothiouracil and methimazole), radioactive iodine, and surgery. Complications of untreated Graves disease are thyroid storm, muscle catabolism with myopathy, and bone catabolism with osteoporosis, among others. Graves disease occurs in 1 in 2,000 people in the United States. A study from Olmstead County, Minnesota, reports an incidence of 30 cases per 100,000 person years. Graves disease is more common in women than in men. There is a marked increase risk of Graves disease in the postpartum period. In men, Graves disease occurs at an older age and frequently is more severe and associated with greater ophthalmopathy. Graves disease occasionally occurs in children and has a high concordance in identical twins. Smoking is associated with an increased risk of Graves disease and Graves ophthalmopathy. Patients have elevated serum thyroxine and low thyroid-stimulating hormone levels. There is an association with HLA-B8 and DR3, and patients may have a familial predisposition to autoimmune disease, including thyroid disease. Thyroid carcinomas occasionally occur in thyroids involved by Graves disease. In a retrospective review of 61 thyroid carcinomas with concurrent Graves disease, 58 papillary carcinomas, 1 follicular carcinoma, 1 Hurthle cell carcinoma, and 1 medullary carcinoma were identified. Most (80 %) of the tumors were 1 cm or smaller. Incidental thyroid carcinomas are less prevalent in Graves disease than in multinodular goiter.
Access provided by Autonomous University of Puebla. Download chapter PDF
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Graves disease, an autoimmune disorder, is the most common cause of hyperthyroidism. Graves disease is associated with antibodies against the thyrotropin receptor that stimulate the receptor and promote synthesis and secretion of thyroglobulin and follicular cell proliferation. Patients present with goiter and symptoms of hyperthyroidism, including anxiety, tachycardia, palpitations, tremor, heat sensitivity, and weight loss, and may develop ophthalmopathy and dermopathy. Patients may be treated symptomatically with β-blockers and with antithyroid medications (propothiouracil and methimazole), radioactive iodine, and surgery. Complications of untreated Graves disease are thyroid storm, muscle catabolism with myopathy, and bone catabolism with osteoporosis, among others. Graves disease occurs in 1 in 2,000 people in the United States. A study from Olmstead County, Minnesota, reports an incidence of 30 cases per 100,000 person years [1]. Graves disease is more common in women than in men. There is a marked increase risk of Graves disease in the postpartum period. In men, Graves disease occurs at an older age and frequently is more severe and associated with greater ophthalmopathy. Graves disease occasionally occurs in children and has a high concordance in identical twins. Smoking is associated with an increased risk of Graves disease and Graves ophthalmopathy [2]. Patients have elevated serum thyroxine and low thyroid-stimulating hormone levels. There is an association with HLA-B8 and DR3, and patients may have a familial predisposition to autoimmune disease, including thyroid disease. Thyroid carcinomas occasionally occur in thyroids involved by Graves disease [3]. In a retrospective review of 61 thyroid carcinomas with concurrent Graves disease, 58 papillary carcinomas, 1 follicular carcinoma, 1 Hurthle cell carcinoma, and 1 medullary carcinoma were identified [4]. Most (80 %) of the tumors were 1 cm or smaller [4]. Incidental thyroid carcinomas are less prevalent in Graves disease than in multinodular goiter [5].
References
Furszyfer J, et al. Graves’ disease in Olmsted County, Minnesota, 1935 through 1967. Mayo Clin Proc. 1970;45(9):636–44.
Balazs C, Stenszky V, Farid NR. Association between Graves’ ophthalmopathy and smoking. Lancet. 1990;336(8717):754.
Brandle M, et al. Medullary thyroid carcinoma in Graves’ disease. Clin Endocrinol. 1999;50(4):545–6.
Chao TC, Lin JD, Chen MF. Surgical treatment of thyroid cancers with concurrent Graves disease. Ann Surg Oncol. 2004;11(4):407–12.
Pascual Corrales E, et al. Incidental differentiated thyroid carcinoma is less prevalent in Graves’ disease than in multinodular goiter. Endocrinol Nutr. 2012;59(3):169–73.
Erickson LA, et al. p27kip1 expression distinguishes papillary hyperplasia in Graves’ disease from papillary thyroid carcinoma. Mod Pathol. 2000;13(9):1014–9.
Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol. 2003;14(1):55–60.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Erickson, L.A. (2014). Graves Disease (Diffuse Hyperplasia). In: Atlas of Endocrine Pathology. Atlas of Anatomic Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0443-3_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0443-3_3
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0442-6
Online ISBN: 978-1-4939-0443-3
eBook Packages: MedicineMedicine (R0)